83 / 84
83
70. Haberhauer G, Strehblow C, Fasching P.
Observational study of switching anti-TNF agents in
ankylosing spondylitis and psoriatic arthritis versus
rheumatoid arthritis. Wien Med Wochenschr
2010;160:220-4.
71. Lie E, van der Heijde D, Uhlig T, Mikkelsen K,
Rødevand E, Koldingsnes W, et al. Effectiveness of
switching between TNF inhibitors in ankylosing
spondylitis: data from the NOR-DMARD register.
Ann Rheum Dis 2011;70:157-63.
72. Braun J, Deodhar A, Dijkmans B, Geusens P,
Sieper J, Williamson P, et al. Efficacy and safety of
infliximab in patients with ankylosing spondylitis
over a two-year period. Arthritis Rheum
2008;59:1270-8.
73. Heldmann F, Brandt J, van der Horst-Bruinsma
IE, Landewe R, Sieper J, Burmester GR, et al. The
European ankylosing spondylitis infliximab cohort
(EASIC): a European multicentre study of long term
outcomes in patients with ankylosing spondylitis
treated with infliximab. Clin Exp Rheumatol
2011;29:672-80.
74. Song IH, Heldmann F, Rudwaleit M, Listing J,
Appel H, Braun J, et al. Different response to
rituximab in tumor necrosis factor blocker-naive
patients with active ankylosing spondylitis and in
patients in whom tumor necrosis factor blockers